Researchers conducted a meta-analysis of 181 publications that contrasted the neural activity of subjects with anxiety with subjects in control groups or healthy subjects in a safe condition with healthy subjects in an unpredictable-threat condition.
The researchers identified greater baseline attachment anxiety and poorer therapeutic alliance as predictors of low treatment response in patients with social anxiety disorder.
Depersonalization can be described as feeling disconnected from one’s body, whereas derealization is characterized by feeling disconnected from the world, with environments, objects, and people seeming unreal or unfamiliar.
The study highlights the significant burden of social anxiety disorder among youth, particularly those with a parental history of psychiatric symptoms.
The FDA has granted Fast Track designation to PH94B (aloradine; VistaGen Therapeutics), a central nervous system neuroactive nasal spray for the on-demand treatment of social anxiety disorder.
A Finnish study published in BMJ found key differences in the conceptions of psychiatric diseases among the general public, physicians, nurses, and legislators.
Data from a multisite study of the effectiveness of cognitive behavioral therapy (CBT) support process-focused CBT as a means of reducing social anxiety.
Compared with other anxiety disorders, social anxiety disorder has a plausible direct influence on alcohol use disorder.
Emerging evidence has begun to elucidate the prevalence and outcomes associated with social anxiety disorder in schizophrenia.
Cognitive therapy is a more effective treatment for social anxiety disorder than paroxetine alone and than pill placebo.
